<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04510129</url>
  </required_header>
  <id_info>
    <org_study_id>PREDAPT</org_study_id>
    <nct_id>NCT04510129</nct_id>
  </id_info>
  <brief_title>A Multicenter Cancer Biospecimen Collection Study</brief_title>
  <official_title>Predicting Immunotherapy Efficacy From Analysis of Pre-treatment Tumor Biopsies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cofactor Genomics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Curebase, Inc.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Cofactor Genomics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will collect de-identified tumor samples, with correlated clinical/demographic&#xD;
      data and tissue histology, from patients selected or scheduled for pre-treatment tumor biopsy&#xD;
      or who have had a recent pre-treatment tumor biopsy. These specimens and clinical data may be&#xD;
      used in subsequent studies for the development and validation of a diagnostic test.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will establish a prospective cohort of pre-treatment tumor specimens with&#xD;
      correlated de-identified clinical and demographic data and tissue histology from cancer&#xD;
      patients who are undergoing treatment with PD-1/PD-L1 inhibitors. Patients who have undergone&#xD;
      pre-anti-PD-1/PD-L1-treatment tumor biopsy or who are scheduled for tumor biopsy prior to&#xD;
      anti-PD-1/PD-L1 treatment will be enrolled.&#xD;
&#xD;
      The study will not require a study-specific tumor biopsy; any biopsies taken prior to&#xD;
      treatment as part of standard of care are eligible for this study. Biopsies must not have&#xD;
      been taken after immunotherapy treatment began.&#xD;
&#xD;
      Participants will be asked to provide their consent for the potential use of their&#xD;
      biospecimens in subsequent studies for the development and validation of a diagnostic test.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 5, 2020</start_date>
  <completion_date type="Anticipated">February 2022</completion_date>
  <primary_completion_date type="Anticipated">February 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>PD-L1/PD-1 inhibitor response</measure>
    <time_frame>6 months</time_frame>
    <description>No response to treatment with PD-L1/PD-1 inhibitor and response to treatment with PD-L1/PD-1 inhibitor.</description>
  </primary_outcome>
  <number_of_groups>11</number_of_groups>
  <enrollment type="Anticipated">1650</enrollment>
  <condition>Cancer of Head and Neck</condition>
  <condition>Lung Cancer, Nonsmall Cell</condition>
  <condition>Small-cell Lung Cancer</condition>
  <condition>Urothelial Carcinoma</condition>
  <condition>Gastroesophageal Junction Adenocarcinoma</condition>
  <condition>Cervical Cancer</condition>
  <condition>Esophageal Squamous Cell Carcinoma</condition>
  <condition>Triple Negative Breast Cancer</condition>
  <condition>Hepatocellular Carcinoma</condition>
  <condition>Renal Cell Carcinoma</condition>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>head and neck squamous cell carcinoma (HNSCC)</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>non-small-cell lung cancer (NSCLC)</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>small cell lung cancer (SCLC)</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>urothelial carcinoma (UCC)</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>gastric or gastroesophageal junction adenocarcinoma</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>cervical cancer</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>esophageal squamous cell carcinoma (ESCC)</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>triple-negative breast cancer (TNBC)</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>hepatocellular carcinoma (HCC)</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>renal cell carcinoma (RCC)</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>colorectal cancer (CRC)</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>OncoPrism™ assay</intervention_name>
    <description>OncoPrism™ is a new approach to characterizing the immune component of pre-treatment tumor tissue.</description>
    <arm_group_label>cervical cancer</arm_group_label>
    <arm_group_label>colorectal cancer (CRC)</arm_group_label>
    <arm_group_label>esophageal squamous cell carcinoma (ESCC)</arm_group_label>
    <arm_group_label>gastric or gastroesophageal junction adenocarcinoma</arm_group_label>
    <arm_group_label>head and neck squamous cell carcinoma (HNSCC)</arm_group_label>
    <arm_group_label>hepatocellular carcinoma (HCC)</arm_group_label>
    <arm_group_label>non-small-cell lung cancer (NSCLC)</arm_group_label>
    <arm_group_label>renal cell carcinoma (RCC)</arm_group_label>
    <arm_group_label>small cell lung cancer (SCLC)</arm_group_label>
    <arm_group_label>triple-negative breast cancer (TNBC)</arm_group_label>
    <arm_group_label>urothelial carcinoma (UCC)</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Sections of subjects' pre-immunotherapy-treatment tumor biopsy, already collected as part of&#xD;
      standard of care, will be collected as part of this study. Biopsy specimens may be used in&#xD;
      subsequent studies for the development and validation of a diagnostic test.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who have undergone pre-anti-PD-1/PD-L1-treatment tumor biopsy or who are scheduled&#xD;
        for tumor biopsy prior to anti-PD-1/PD-L1 treatment will be enrolled.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subject must have a disease of interest. Specifically, subject must have one of:&#xD;
&#xD;
               1. head and neck squamous cell carcinoma (HNSCC)&#xD;
&#xD;
               2. non-small-cell lung cancer (NSCLC)&#xD;
&#xD;
               3. small cell lung cancer (SCLC)&#xD;
&#xD;
               4. urothelial carcinoma (UCC)&#xD;
&#xD;
               5. gastric or gastroesophageal junction adenocarcinoma&#xD;
&#xD;
               6. cervical cancer&#xD;
&#xD;
               7. esophageal squamous cell carcinoma (ESCC)&#xD;
&#xD;
               8. triple-negative breast cancer (TNBC)&#xD;
&#xD;
               9. hepatocellular carcinoma (HCC)&#xD;
&#xD;
              10. renal cell carcinoma (RCC)&#xD;
&#xD;
              11. colorectal cancer (CRC)&#xD;
&#xD;
          2. Subject must have received, or be scheduled to receive, at least one dose of&#xD;
             anti-PD-1/PD-L1 immunotherapy for treatment of their cancer.&#xD;
&#xD;
          3. Subject must have had, or will have, a tumor biopsy prior to treatment with&#xD;
             anti-PD-1/PD-L1 immunotherapy.&#xD;
&#xD;
          4. Subject must have undergone, or will undergo, medical imaging (e.g. CT or MRI) of the&#xD;
             tumor prior to treatment with anti-PD-1/PD-L1 immunotherapy.&#xD;
&#xD;
          5. Willing to provide electronic informed consent per IRB-approved protocol.&#xD;
&#xD;
          6. Able to speak, read, and comprehend English fluently.&#xD;
&#xD;
          7. Subject is 18 years of age or older.&#xD;
&#xD;
          8. Subjects must have sufficient tissue available to fulfill the specimen requirements of&#xD;
             the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Inability or unwillingness to provide informed consent.&#xD;
&#xD;
          2. Subject who does/did not have one of the cancers listed above (other histologies).&#xD;
&#xD;
          3. Subject has already participated in this trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Adam Samson, MS</last_name>
    <phone>919-995-3511</phone>
    <email>adam@curebase.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hannah Gittleman</last_name>
    <phone>415-730-5547</phone>
    <email>hannah@curebase.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Curebase</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94131</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adam Samson, MS</last_name>
      <phone>919-995-3511</phone>
      <email>adam@curebase.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://web.curebase.com/study/predapt</url>
    <description>Participant Recruitment Website</description>
  </link>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>August 10, 2020</study_first_submitted>
  <study_first_submitted_qc>August 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 12, 2020</study_first_posted>
  <last_update_submitted>July 26, 2021</last_update_submitted>
  <last_update_submitted_qc>July 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
    <mesh_term>Triple Negative Breast Neoplasms</mesh_term>
    <mesh_term>Esophageal Squamous Cell Carcinoma</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

